Generation, intracellular transport and loading of peptides associated with MHC class I molecules

Current Opinion in Immunology

Volumn 9, Issue 1, 1997, Pages 80-88

  Koopmann, Jens Oliver ^a   Hämmerling, Günter J ^a   Momburg, Frank ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE;

ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL DIVISION; CHROMATIN STRUCTURE; CYTOPLASM; ENDOPLASMIC RETICULUM; INTRACELLULAR TRANSPORT; MAJOR HISTOCOMPATIBILITY COMPLEX;

EID: 0342894676     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80163-X     Document Type: Article

References (90)

1. Germain RN. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell. 76:1994;287-299.
2. Rammensee H-G, Falk K, Rötzschke O. Peptides naturally presented by MHC class I molecules. Ann Rev Immunol. 11:1993;213-244.
3. Heemels M-T, Ploegh H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem. 64:1995;463-491.
4. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 267:1995;243-246.
5. Norbury CC, Hewlett LJ, Prescott AR, Shastri N, Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity. 3:1995;783-791.
6. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 183:1996;317-322.
7. Goldberg AL, Rock KL. Proteolysis, proteasomes and antigen presentation. Nature. 357:1992;375-379.
8. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 356:1992;443-446.
9. Elliott T, Willis A, Cerundolo V, Townsend A. Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum. J Exp Med. 181:1995;1481-1491.
10. + CTL. J Immunol. 154:1995;6140-6156.
11. Koster AJ, Walz J, Lupas A, Baumeister W. Structural features of archaebacterial and eukaryotic proteasomes. Mol Biol Rep. 21:1996;11-20.
12. Tanaka K. Molecular biology of proteasomes. Mol Biol Rep. 21:1996;21-26.
13. Lehner PJ, Cresswell P. Processing and delivery of peptides presented by MHC class I molecules. Curr Opin Immunol. 8:1996;59-67.
14. Groettrup M, Soza A, Kuckelkom U, Kloetzel P-M. Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today. 17:1996;429-435.
15. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 78:1994;761-771.
16. Harding CV, France J, Song R, Farah JM, Chatterjee S, Iqbal M, Siman R. Novel dipeptide aldehydes are proteasome inhibitors and block the MHC-I antigen-processing pathway. J Immunol. 155:1995;1767-1775.
17. Hughes EA, Ortmann B, Surman M, Cresswell P. The protease inhibitor, N-acetyl-L-leucyl-L-leucyl-L-norleucinal, decreases the pool of major histocompatibility complex class I-binding peptides and inhibits peptide trimming in the endoplasmic reticulum. J Exp Med. 183:1996;1569-1578.
18. Yang B, Hahn YS, Hahn CS, Braciale TJ. The requirement for proteasome activity in class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. J Exp Med. 183:1996;1545-1552.
19. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 268:1995;726-731.
20. Dick LR, Aldrich C, Jameson SC, Moomaw CR, Pramanik BC, Doyle CK, DeMartino GN, Bevan MJ, Forman JM, Slaughter CA. Proteolytic processing of ovalbumin and β-galactosidase by the proteasome to yield antigenic peptides. J Immunol. 152:1994;3884-3894.
21. Niedermann G, Butz S, Ihlenfeldt HG, Grimm R, Lucchiari M, Hoschützky H, Jung G, Maier B, Eichmann K. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. of special interest Immunity. 2:1995;289-299 This paper connects the cleavage preferences of 20S proteasomes with the immunodominance versus subdominance of ovalbumin epitopes.
22. Niedermann G, King G, Butz S, Birsner U, Grimm R, Shabanowitz J, Hunt DF, Eichmann K. The proteolytic fragments generated by vertebrate proteasomes: Structural relationships to major histocompatibility complex class I binding peptides. Proc Natl Acad Sci USA. 93:1996;8572-8577.
23. Eggers M, Boes-Fabian B, Ruppert T, Kloetzel P-M, Koszinowski UH. The cleavage preference of the proteasome governs the yield of antigenic peptides. J Exp Med. 182:1995;1865-1870.
24. Del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighbouring residues in the protein. Cell. 66:1991;1145-1153.
25. Ossendorp F, Eggers M, Neisig A, Ruppert T, Groettrup M, Sijts A, Mengedé E, Kloetzel P-M, Neefjes J, Koszinowski U, Melief C. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. of special interest Immunity. 5:1996;115-124 This paper shows a novel mechanism of viral immune evasion: epitope destruction by proteasomal cleavage.
26. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 79:1994;13-21.
27. Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, Coupar B, Boyle D, Chan S, Smith G. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med. 168:1988;1211-1224.
28. Michalek MT, Grant EP, Rock KL. Chemical denaturation and modification of ovalbumin alters its dependence on ubiquitin conjugation for class I antigen presentation. J Immunol. 157:1996;617-624 This study points to a role of ubiquitin-independent proteasomal processing of endogenously synthesized antigens.
29. Grant EP, Michalek MT, Goldberg AL, Rock KL. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J Immunol. 155:1995;3750-3758.
30. Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H, Rammensee H-G, Koszinowski UH, Kloetzel P-M. A role for the proteasome regulator PA28α in antigen presentation. of special interest Nature. 381:1995;166-168 An enhancing effect of the PA28 activator complex on the generation of class I binding antigenic peptides is demonstrated in vivo [30] and in vitro [31].
31. Dick TP, Ruppert T, Groettrup M, Kloetzel PM, Kuehn L, Koszinowski UH, Stevanovic S, Schild H, Rammensee H-G. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell. 86:1996;253-262 See annotation [30].
32. Griem P, Wallny H-J, Falk K, Rötzschke O, Arnold B, Schönrich G, Hämmerling GJ, Rammensee H-G. Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression. Cell. 65:1991;633-640.
33. Sijts AJAM, Neisig A, Neefjes J, Pamer EC. Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. J Immunol. 156:1996;685-692.
34. Srivastava PK, Udono H, Blachere NE, Li Z. Hypothesis: heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics. 39:1994;93-98.
35. Nadeau K, Nadler SG, Saulnier M, Tepper MA, Walsh CT. Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry. 33:1994;2561-2567.
36. Howard JC. Supply and transport of peptides presented by class I MHC molecules. Curr Opin Immunol. 7:1995;69-76.
37. Kleijmeer MJ, Kelly A, Geuze HJ, Slot JW, Townsend A, Trowsdale J. Location of MHC-encoded transporters in the endoplasmic reticulum and cis-Golgi. Nature. 357:1992;342-344.
38. Russ G, Esquivel F, Yewdell JW, Cresswell P, Spies T, Bennink JR. Assembly, intracellular localization, and nucleotide binding properties of the human peptide transporters TAP1 and TAP2 expressed by recombinant vaccinia viruses. J Biol Chem. 270:1995;21312-21318.
39. Neefjes JJ, Momburg F, Hämmerling GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded peptide transporter. Science. 261:1993;769-771.
40. Heemels M-T, Schumacher TNM, Wonigeit K, Ploegh HL. Peptide translocation by variants of the transporter associated with antigen processing. Science. 262:1993;2059-2063.
41. Roelse J, Grommé M, Momburg F, Hämmerling GJ, Neefjes J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med. 180:1994;1591-1597.
42. Schumacher TNM, Kantesaria DV, Heemels M-T, Ashton-Rickardt PG, Shepherd JC, Früh K, Yang Y, Peterson PA, Tonegawa S, Ploegh HL. Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. J Exp Med. 179:1994;533-540.
43. Yang B, Braciale TJ. Characteristics of ATP-dependent peptide transport in isolated microsomes. of special interest J Immunol. 155:1995;3889-3896 This paper provides the first kinetic values for TAP-mediated peptide transport.
44. Momburg F, Roelse J, Hämmerling GJ, Neefjes JJ. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J Exp Med. 179:1994;1613-1623.
45. Androlewicz MJ, Cresswell P. Human transporters associated with antigen processing possess a promiscuous peptide-binding site. Immunity. 1:1994;7-14.
46. Heemels M-T, Ploegh HL. Substrate specificity of allelic variants of the TAP peptide transporter. Immunity. 1:1994;775-784.
47. Koopmann J-O, Post M, Neefjes JJ, Hämmerling GJ, Momburg F. Translocation of long peptides by transporters associated with antigen processing (TAP). of special interest Eur J Immunol. 26:1996;1720-1728 This study shows that peptides up to 40 amino acids can be substrates for TAP, but optimal transport is obtained with 8-12 mers.
48. Urban RG, Chicz RM, Lane WS, Strominger JL, Rehm A, Kenter MJH, UytdeHaag FGCM, Ploegh H, Uchanska-Ziegler B, Ziegler A. A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci USA. 91:1994;1534-1538.
49. Momburg F, Roelse J, Howard JC, Butcher GW, Hämmerling GJ, Neefjes JJ. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature. 367:1994;648-651.
50. Neefjes J, Gottfried E, Roelse J, Grommé M, Obst R, Hämmerling GJ, Momburg F. Analysis of the fine specificity of rat, mouse and human TAP peptide transporters. Eur J Immunol. 25:1995;1133-1136.
51. Neisig A, Roelse J, Sijts AJAM, Ossendorp F, Feltkamp MCW, Kast WM, Melief CJM, Neefjes JJ. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J Immunol. 154:1995;1273-1279.
52. Gournier H, Pascolo S, Siegrist C-A, Jehan J, Pérarnau B, Garcia Z, Rose T, Neefjes J, Lemonnier FA. Restriction of self-antigen presentation to cytolytic T lymphocytes by mouse peptide pumps. Eur J Immunol. 25:1995;2019-2026.
53. Van Endert PM, Tampé R, Meyer TH, Tisch R, Bach J-F, McDevitt HO. A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity. 1:1994;491-500.
54. Van Endert PM, Riganelli D, Greco G, Fleischhauer K, Sidney J, Sette A, Bach J-F. The peptide-binding motif for the human transporter associated with antigen processing. of special interest J Exp Med. 182:1995;1883-1895 Based on an investigation of numerous peptides, this paper delineates residues that are important for binding to TAP.
55. Uebel S, Meyer TH, Kraas W, Kienle S, Jung G, Wiesmüller K-H, Tampé R. Requirements for peptide binding to the human transporter associated with antigen processing revealed by peptide scans and complex peptide libraries. J Biol Chem. 270:1995;18512-18516.
56. Powis SJ, Young LL, Joly E, Barker PJ, Richardson L, Brandt RP, Melief CJ, Howard JC, Butcher GW. The rat cim effect: TAP allele-dependent changes in a class I MHC anchor motif and evidence against carboxy-terminal trimming of peptides in the ER. of special interest Immunity. 4:1996;159-165 This paper, together with [57], demonstrates strong effects of selective peptide transport in class I loading in vivo.
57. Simmons WA, Leong LYW, Satumtira N, Butcher GW, Howard JC, Richardson JA, Slaughter CA, Hammer RE, Taurog JD. Rat MHC-linked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease. J Immunol. 156:1996;1661-1667.
58. Obst R, Armandola EA, Nijenhuis M, Momburg F, Hämmerling GJ. TAP polymorphism does not influence transport of peptide variants in mice and humans. Eur J Immunol. 25:1995;2170-2176.
59. g7 (NOD/Lt) haplotype translocate similar peptides. Proc Natl Acad Sci USA. 91:1994;13004-13008.
60. Lobigs M, Rothenfluh HS, Blanden RV, Müllbacher A. Polymorphic peptide transporters in MHC class I monomorphic Syrian hamster. of special interest Immunogenetics. 42:1995;398-407 This paper provides evidence that the class I monomorphic Syrian hamster expresses functionally polymorphic TAPs.
61. Powis SJ, Deverson EV, Coadwel WJ, Ciruela A, Huskisson NS, Smith H, Butcher GW, Howard JC. Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature. 357:1992;211-215.
62. Momburg F, Armandola EA, Post M, Hämmerling GJ. Residues in TAP2 peptide transporters controlling substrate specificity. of special interest J Immunol. 156:1996;1756-1763 This study identifies polymorphic TAP2 residues that control permissive versus selective transport patterns in the rat.
63. Armandola EA, Momburg F, Nijenhuis M, Bulbuc N, Früh K, Hämmerling GJ. A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. Eur J Immunol. 26:1996;1748-1755.
64. 2-microglobulin binding to the transporter associated with antigen processing (TAP1 and TAP2). Proc Natl Acad Sci USA. 91:1994;12716-12720.
65. Nijenhuis M, Schmitt S, Armandola EA, Obst R, Brunner J, Hämmerling GJ. Identification of a contact region for peptide on the TAP1 chain of the transporter associated with antigen processing. J Immunol. 156:1996;2186-2195 By photoaffinity labeling, TAP1 domains are mapped that are involved in peptide binding.
66. Nijenhuis M, Hämmerling GJ. Multiple regions of the transporter associated with antigen processing (TAP) contribute to its binding site. J Immunol. 157:1997;5467-5477.
67. Hill A, Ploegh H. Getting the inside out: the transporter associated with antigen processing (TAP) and the presentation of viral antigen. Proc Natl Acad Sci USA. 92:1995;341-343.
68. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D. Herpes simplex virus turns off the TAP to evade host immunity. of special interest Nature. 375:1995;411-415 Together with [69], this paper shows the inhibition of peptide transport by the cytosolic Herpes simplex virus protein ICP47.
69. Früh K, Ahn K, Djaballah H, Sempé P, Van Endert PM, Tampé R, Peterson PA, Yang Y. A viral inhibitor of peptide transporters for antigen presentation. of special interest Nature. 375:1995;415-418 See annotation [68].
70. Ahn K, Meyer TH, Uebel S, Sempé P, Djaballah H, Yang Y, Peterson PA, Früh K, Tampé R. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus protein ICP47. EMBO J. 15:1996;3247-3255.
71. Tomazin R, Hill AB, Jugovic P, York I, van Endert P, Ploegh HL, Andrews DW, Johnson DC. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J. 15:1996;3256-3266.
72. Hengel H, Flohr T, Hämmerling GJ, Koszinowski UH, Momburg F. Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. of special interest J Gen Virol. 77:1996;2287-2296 This paper shows that an early gene product of human cytomegalovirus blocks peptide transport.
73. 2-microglobulin and peptide. J Exp Med. 175:1992;1653-1661.
74. Sugita M, Brenner MB. An unstable β2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide. J Exp Med. 180:1994;2163-2171.
75. Vassilakos A, Cohen-Doyle M, Peterson PA, Jackson MR, Williams DB. The molecular chaperone calnexin facilitates folding and assembly of class I histocompatibility molecules. EMBO J. 15:1996;1495-1506.
76. Nöβner E, Parham P. Species-specific differences in chaperone interaction of human and mouse histocompatibility complex class I molecules. J Exp Med. 181:1995;327-337.
77. 2m heterodimers can also be detected in association with calnexin. See also annotation [81].
78. Scott JE, Dawson JR. MHC class I expression and transport in a calnexin-deficient cell line. J Immunol. 155:1995;143-148.
79. Balow JP, Weissman JD, Kearse KP. Unique expression of the major histocompatibility complex class I proteins in the absence of glucose trimming and calnexin association. J Biol Chem. 270:1995;29025-29029.
80. Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. of outstanding interest Immunity. 5:1996;103-114 The first description of calreticulin and tapasin as being components of the transient class I-TAP complex. 721.220 cells are shown to lack tapasin (see [85]).
81. 3 domain can abrogate TAP association.
82. 2-microglobulin complexes associate with TAP transporters before peptide binding. Nature. 368:1994;864-867.
83. Suh W-K, Cohen-Doyle MF, Früh K, Wang K, Peterson PA, Williams DB. Interaction of MHC class I molecules with the transporter associated with antigen processing. Science. 264:1994;1322-1326.
84. 2-miroglobulin, class I heavy chain conformation, and tapasin in the interactions of class I heavy chain with calreticulin and the transporter associated with antigen processing. J Immunol. 1997;. in press.
85. Grandea AG III, Androlewicz MJ, Athwal RS, Geraghty DE, Spies T. Dependence of peptide binding by MHC class I molecules on their interaction with ATP. of outstanding interest Science. 270:1995;105-108 Due to a gene defect on chromosome 6, class I molecules in 721.220 mutant cells fail to interact with TAP. See also annotation [80].
86. Greenwood R, Shimizu Y, Sekhon GS, DeMars R. Novel allele-specific, post-translational reduction in HLA class I surface expression in a human B cell line. J Immunol. 153:1994;5525-5536.
87. Neisig A, Wubbolts R, Zang X, Melief C, Neefjes J. Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. of special interest J Immunol. 156:1996;3196-3206 This study demonstrates a low degree of TAP association for some HLA-B alleles.
88. 2 domain for the interaction with accessory molecules in the ER.
89. Lewis JW, Neisig A, Neefjes J, Elliott T. Point mutations in the α2 domain of HLA-A2.1 define a functionally relevant interaction with TAP. of special interest Curr Biol. 6:1996;873-883 See annotation [88].
90. Löwe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome form the archaeon T. acidophilum at 3.4 Å resolution. of outstanding interest Science. 268:1995;533-539 The structure of an archaebacterial proteasome is revealed by X-ray crystallography. By labelling with a peptide aldehyde inhibitor, active sites on β subunits were identified that point towards the central cavity of the proteasome.